Is ALVO a Buy or a Sell? The Bull and Bear Case (2026)

Last updated July 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Alvotech (ALVO) rests on Three FDA decisions in one December week: AVT05 (a biosimilar to Simponi and Simponi Aria), AVT06 (Eylea) and AVT03 (Prolia and Xgeva) were all resubmitted in June 2026 under a six month review clock that points to early December. The bear case rests on leverage is the dominant risk: roughly $1.31 billion of borrowings against $142.8 million of cash mid-year, a net-debt-to-adjusted-EBITDA ratio above 9x at the end of 2025, and a new term loan carrying 12.50% cash interest maturing December 2027. Analysts covering it publish targets from $4.00 to $9.00 against a $5.87 price, so even the professionals disagree by 74% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

Alvotech develops and manufactures biosimilars, which are approved copies of biologic medicines whose patents have run out, and then hands the selling to partners rather than building its own sales force. Teva covers the United States, Advanz Pharma covers Europe, the UK, Switzerland, Canada and Australia, Dr. Reddy's carries denosumab and is co-developing a Keytruda biosimilar, and Sandoz picked up Canadian and ANZ rights in early 2026. Five biosimilars now produce revenue: adalimumab, ustekinumab, golimumab, aflibercept and denosumab. Money arrives in two very different shapes, product supply to those partners and lumpy licensing and milestone payments, which is why half-year comparisons swing hard. First-half 2026 revenue was about $211.9 million, split almost evenly between roughly $105.9 million of product and $105.7 million of licensing, against $306.1 million a year earlier when milestones happened to land in the period. The investment picture turns on one date. On November 2, 2025, the FDA issued a complete response letter for AVT05, the golimumab biosimilar, and the shares fell about 34% to $5.03 the next day. Related manufacturing findings at the Reykjavik plant also held up AVT06 (aflibercept) and AVT03 (denosumab). That inspection has since closed with a voluntary action indicated classification, the applications were resubmitted in June 2026, and the FDA review goal points to decisions around December 4. Management reaffirmed 2026 guidance of $650 million to $700 million in revenue and $180 million to $220 million in adjusted EBITDA, but only $46.9 million of that EBITDA arrived in the first half, so the guide leans almost entirely on the fourth quarter. Behind it sits about $1.31 billion of borrowings, $142.8 million of cash at June 30, a $165 million equity raise in June that diluted existing holders, and a new $75 million term loan priced at 12.50%. Barclays moved the stock two notches to Overweight in September with an $8 target; the broader analyst average sits near $6.80.

The bull case: what would have to be true for $9.00

The most optimistic published target on ALVO is $9.00, +53.3% from the $5.87 price as of September 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Three FDA decisions in one December week

AVT05 (a biosimilar to Simponi and Simponi Aria), AVT06 (Eylea) and AVT03 (Prolia and Xgeva) were all resubmitted in June 2026 under a six month review clock that points to early December. Approval would put three new molecules into Teva's and Dr. Reddy's US channels and unlock milestone payments management has sized in the hundreds of millions. A second round of deficiency letters would do the opposite, and would land on a company with far less financial slack than it had a year ago.

2. Five products already generating cash

This is not a pre-revenue story. Adalimumab, ustekinumab, golimumab, aflibercept and denosumab are selling in markets outside the US, gross margin held near 54% in the first half, and adjusted EBITDA has been positive through the disruption. The installed base is what funds the interest bill while the US approvals are pending.

3. A pipeline that keeps feeding the same plant

AVT16 (a biosimilar to Entyvio) has been accepted by the FDA and validated by the EMA, AVT80 is in European review, and the Keytruda biosimilar co-developed with Dr. Reddy's targets one of the largest drug franchises in the world late this decade. Each additional molecule spreads the fixed cost of the Reykjavik and Jurong facilities over more volume, which is the entire economic argument for a dedicated biosimilars manufacturer.

4. Partners carry the commercial cost

Alvotech sells through Teva, Advanz, Dr. Reddy's and Sandoz instead of funding country-by-country sales teams. That keeps operating expense lighter than a fully integrated pharma company and gives access to formularies Alvotech could not reach alone. The trade is that partners take a share of the economics and control launch timing, so approval alone does not set the pace of revenue.

The bear case: what would have to be true for $4.00

The most pessimistic published target is $4.00, -31.9% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Alvotech is worth if the risks below bite instead of the drivers above.

Leverage is the dominant risk: roughly $1.31 billion of borrowings against $142.8 million of cash mid-year, a net-debt-to-adjusted-EBITDA ratio above 9x at the end of 2025, and a new term loan carrying 12.50% cash interest maturing December 2027. Management has stated the company remains a going concern while noting it may need further financing if cash generation lags, and the June equity raise showed what closing that gap costs existing holders. The 2026 guide requires a fourth quarter far larger than the first half delivered, which makes it unusually dependent on approvals and milestone recognition arriving on schedule. Several plaintiff law firms, including Rosen, Hagens Berman and Levi and Korsinsky, have publicised investigations into the disclosures that preceded the November 2025 complete response letter, though no filed complaint or lead plaintiff deadline has been made public. Underneath all of it, biosimilar pricing erodes quickly once several competitors clear the same molecule, so an approval that arrives into a crowded market is worth much less than the first one in.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ALVO already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on ALVO

5 analysts cover ALVO, with an average target of $6.80 (+15.8% against $5.87) and a split of 6 buy, 1 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the ALVO forecast and price target page.

How is ALVO valued? (as of September 2026)

Price

$5.87

Market cap

$2.09B

Forward P/E

25.71

Beta

0.22

52-week range

$2.94 to $9.25

Snapshot for ALVO as of September 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$495 million
2026 revenue guidance: ~$650M to $700M
Adjusted EBITDA (H1 2026): ~$46.9 million
Net loss (TTM): ~$180 million
Market cap: ~$2.1 billion
Net debt: ~$1.3 billion

Adding roughly $1.3 billion of net debt to a $2.1 billion market cap puts enterprise value near $3.4 billion, about 17 times the midpoint of 2026 adjusted EBITDA guidance and roughly 3 times guided revenue. Those multiples only hold if the second half arrives as guided, because the first half produced about a quarter of the full-year EBITDA target. The shares have traded between $2.94 and $9.25 over the past year, a range that says more about how the market prices the regulatory outcome than about the operating business.

How do you decide if ALVO is a buy?

Rather than asking whether ALVO is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold ALVO indirectly through an index or sector ETF before adding more.

What would change your mind on ALVO

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: Three FDA decisions in one December week stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: leverage is the dominant risk: roughly $1.31 billion of borrowings against $142.8 million of cash mid-year, a net-debt-to-adjusted-EBITDA ratio above 9x at the end of 2025, and a new term loan carrying 12.50% cash interest maturing December 2027 fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the ALVO stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ALVO against your real portfolio and see your actual exposure before deciding.

Investing in Alvotech with AI

Connect the broker you already use and ask Walnut's AI how ALVO fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does ALVO fit me?

FAQ

Is ALVO a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on Three FDA decisions in one December week, with revenue (ttm) at ~$495 million. The bear case rests on leverage is the dominant risk: roughly $1.31 billion of borrowings against $142.8 million of cash mid-year, a net-debt-to-adjusted-EBITDA ratio above 9x at the end of 2025, and a new term loan carrying 12.50% cash interest maturing December 2027. Analysts covering it are spread from $4.00 to $9.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell ALVO?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Leverage is the dominant risk: roughly $1.31 billion of borrowings against $142.8 million of cash mid-year, a net-debt-to-adjusted-EBITDA ratio above 9x at the end of 2025, and a new term loan carrying 12.50% cash interest maturing December 2027. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $4.00, -31.9% from the $5.87 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for ALVO?

Three FDA decisions in one December week. AVT05 (a biosimilar to Simponi and Simponi Aria), AVT06 (Eylea) and AVT03 (Prolia and Xgeva) were all resubmitted in June 2026 under a six month review clock that points to early December. The most optimistic analyst target on ALVO is $9.00, +53.3% from the $5.87 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for ALVO?

What does Alvotech do?

Iceland-based pure-play developer and manufacturer of biosimilars, approved copies of off-patent biologic medicines, sold through partners such as Teva and Advanz rather than its own sales force.

What would have to change for ALVO to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Three FDA decisions in one December week) stalling in the reported numbers rather than in the narrative, the risk above (leverage is the dominant risk: roughly $1.31 billion of borrowings against $142.8 million of cash mid-year, a net-debt-to-adjusted-EBITDA ratio above 9x at the end of 2025, and a new term loan carrying 12.50% cash interest maturing December 2027) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Alvotech actually sell?

Biosimilars, meaning approved copies of biologic drugs whose patents have expired. Five are commercial today: adalimumab, ustekinumab, golimumab, aflibercept and denosumab. Alvotech develops and manufactures them in Reykjavik and Singapore, then supplies partners who handle marketing and distribution in each region.

Why did ALVO fall so sharply in November 2025?

On November 2, 2025 the FDA issued a complete response letter for AVT05, the golimumab biosimilar, citing deficiencies that had to be resolved before approval. The stock fell about 34% the following session to close at $5.03. Manufacturing findings from the same inspection also delayed the aflibercept and denosumab applications.

What is the December 2026 FDA date about?

Alvotech resubmitted the AVT05, AVT06 and AVT03 applications in June 2026 after closing out the Reykjavik inspection, which the FDA classified as voluntary action indicated. A standard six month review implies decisions around December 4, 2026. Three US approvals in one stroke is the single largest swing factor in the company's 2027 numbers.

Walnut is informational, not investment advice, and gives no verdict on ALVO. Analyst targets referenced here come from a September 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.